These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 26930292

  • 1. Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis.
    Ma Z, Li Y, Zhou M, Huang K, Hu H, Liu X, Xu X.
    PLoS One; 2016; 11(3):e0150203. PubMed ID: 26930292
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
    McClung MR, Bolognese MA, Sedarati F, Recker RR, Miller PD.
    Bone; 2009 Mar; 44(3):418-22. PubMed ID: 18950736
    [Abstract] [Full Text] [Related]

  • 5. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial.
    Recknor C, Czerwinski E, Bone HG, Bonnick SL, Binkley N, Palacios S, Moffett A, Siddhanti S, Ferreira I, Ghelani P, Wagman RB, Hall JW, Bolognese MA, Benhamou CL.
    Obstet Gynecol; 2013 Jun; 121(6):1291-1299. PubMed ID: 23812464
    [Abstract] [Full Text] [Related]

  • 6. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.
    Hakala M, Kröger H, Valleala H, Hienonen-Kempas T, Lehtonen-Veromaa M, Heikkinen J, Tuomiranta T, Hannonen P, Paimela L, ONCE trial group.
    Scand J Rheumatol; 2012 Aug; 41(4):260-6. PubMed ID: 22803768
    [Abstract] [Full Text] [Related]

  • 7. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH, Ensrud KE, Burdeska A, Mills T, Oral Ibandronate Study Group.
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [Abstract] [Full Text] [Related]

  • 8. Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate.
    Miller PD, Delmas PD, Huss H, Patel KM, Schimmer RC, Adami S, Recker RR.
    Calcif Tissue Int; 2010 Oct; 87(4):305-13. PubMed ID: 20737140
    [Abstract] [Full Text] [Related]

  • 9. Oral weekly ibandronate prevents bone loss in postmenopausal women.
    Tankó LB, Felsenberg D, Czerwiński E, Burdeska A, Jonkanski I, Hughes C, Christiansen C, Oral Ibandronate Group.
    J Intern Med; 2003 Aug; 254(2):159-67. PubMed ID: 12859697
    [Abstract] [Full Text] [Related]

  • 10. Alfacalcidol Increases the Therapeutic Efficacy of Ibandronate on Bone Mineral Density in Japanese Women with Primary Osteoporosis.
    Nakamura Y, Suzuki T, Kamimura M, Ikegami S, Uchiyama S, Kato H.
    Tohoku J Exp Med; 2017 Apr; 241(4):319-326. PubMed ID: 28458336
    [Abstract] [Full Text] [Related]

  • 11. Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis.
    Engelke K, Fuerst T, Dasic G, Davies RY, Genant HK.
    Bone; 2010 Jun; 46(6):1626-32. PubMed ID: 20226286
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of ibandronate given by intravenous injection once every 3 months.
    Adami S, Felsenberg D, Christiansen C, Robinson J, Lorenc RS, Mahoney P, Coutant K, Schimmer RC, Delmas PD.
    Bone; 2004 May; 34(5):881-9. PubMed ID: 15121020
    [Abstract] [Full Text] [Related]

  • 13. Dose-Effectiveness Relationships Determining the Efficacy of Ibandronate for Management of Osteoporosis: A Meta-Analysis.
    Hou Y, Gu K, Xu C, Ding H, Liu C, Tuoheti Y.
    Medicine (Baltimore); 2015 Jul; 94(26):e1007. PubMed ID: 26131800
    [Abstract] [Full Text] [Related]

  • 14. The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast.
    Tankó LB, McClung MR, Schimmer RC, Mahoney P, Christiansen C.
    Bone; 2003 Apr; 32(4):421-6. PubMed ID: 12689686
    [Abstract] [Full Text] [Related]

  • 15. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
    Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM.
    Arthritis Rheum; 2006 Jun; 54(6):1838-46. PubMed ID: 16729277
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of monthly intravenous ibandronate on the low responders to oral bisphosphonate: the MOVEMENT study.
    Hagino H, Sakai A, Ikeda S, Imanishi Y, Tsurukami H, Nakajo S, Miyakoshi N.
    J Bone Miner Metab; 2019 Nov; 37(6):1013-1023. PubMed ID: 31098670
    [Abstract] [Full Text] [Related]

  • 17. Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis.
    Sebba AI, Emkey RD, Kohles JD, Sambrook PN.
    Bone; 2009 Mar; 44(3):423-7. PubMed ID: 19049913
    [Abstract] [Full Text] [Related]

  • 18. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M, Viapiana O, Gatti D, Adami S.
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [Abstract] [Full Text] [Related]

  • 19. Monthly oral ibandronate 100 mg is as effective as monthly intravenous ibandronate 1 mg in patients with various pathologies in the MOVEST study.
    Hagino H, Ito M, Hashimoto J, Yamamoto M, Endo K, Katsumata K, Asao Y, Matsumoto R, Nakano T, Mizunuma H, Nakamura T.
    J Bone Miner Metab; 2018 May; 36(3):336-343. PubMed ID: 28389932
    [Abstract] [Full Text] [Related]

  • 20. Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis.
    Nakamura T, Ito M, Hashimoto J, Shinomiya K, Asao Y, Katsumata K, Hagino H, Inoue T, Nakano T, Mizunuma H, MOVEST Study Group.
    Osteoporos Int; 2015 Nov; 26(11):2685-93. PubMed ID: 26001561
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.